Another Haircut with Avy the Barber
SoFi’s stock case hinges on interest rates, tangible book value and private-credit loan sales after its $1.5 billion equity offering.
SoFi’s stock case hinges on interest rates, tangible book value and private-credit loan sales after its $1.5 billion equity offering.
@TimelessArie Ticker is $INVH for those curious
More $CUBE news Sold 80% to Heitman in a JV valued $197mm at a roughly mid 5% cap rate and used proceeds to buy back better assets like those in NYC in that 6.3% to 6.5% cap rate range Improves quality and sell non-core at lower cap rate than higher quality assets Retains management and builds annuity mgt fee stream
Thats cool $GOOG shareholders lost around $500B today https://t.co/ejv9K0CnIy
I have consistently talked about buying $CUBE in the past year and highlighted their incredible NYC/NNJ portfolio It accounts for 1/4 of the company's NOI, up 5.5% in Q3 on a YOY basis. Moves the needle. Overall NOI up 2.1% YOY High barrier, no rent regs like housing, truly a great asset NOI declines mostly in Sunbelt high supply markets Story is as old as time Bought at a rough 6.7% cap about a year ago at $36 ish now $41.08 plus about $2.12 in dividends since Not too shabby for a 20% one year return for buying a high quality SS with low leverage
Roblox Narrows Loss as User, Engagement Metrics Fall The video-game company said average daily users were down 9% to 138 million, and engagement hours fell 15% to 34 billion. $RBLX https://t.co/KQM4qbpsbd
$PURR https://t.co/yeJJ2cHVeE
Alphabet's EPS miss came from a SpaceX stake loss, while 24.7% revenue growth and a $561 billion Cloud backlog counter free cash flow…
Incyte reported Q3 FY26 revenue of $1.56 billion, up 14%, while a $1.23 billion Vega acquisition charge drove a $708 million operating loss.
Merck reported Q3 FY26 revenue of $18.1 billion, led by $8.6 billion in KEYTRUDA sales and 93% WINREVAIR growth, while raising and…
Alphabet’s Search growth slowed to 12% as Cloud revenue more than doubled, while quarterly free cash flow stayed negative amid the capex…
CoStar’s 3Q26 revenue growth slowed to 14% as bookings fell to $37 million, while cost cuts lifted EBIT margin to 8.8%.
Simran Jeet Singh recounts pricing oil through WTI’s -$37.63 collapse, then explains crypto perpetual funding arbitrage, market making and…
Carpenter Technology fell 25% after Q1 2027 despite revenue rising 9%, EPS up 34%, and commercial aerospace bookings up 25%.
GE Vernova raised guidance for a third straight quarter as Power and Electrification drove backlog growth, while Wind showed an early…
Alphabet reported $127.6 billion in revenue, up 25%, as Google Cloud doubled to $30.7 billion and 36.2% margins.
Alamos Gold targets nearly 1 Moz of annual production by decade-end as Island Gold shaft commissioning offsets recent Young-Davidson…
Monster Beverage’s modified Dutch auction lets odd-lot holders buy 99 MNST shares below $53 and tender them at $53 to $60.
Roaring Kitty’s GameStop resurgence revisits GME shareholder activism and the meme-stock trading episode, with references to Bed Bath &…
CVS Health fell 20% after cutting 2024 adjusted EPS guidance to $7, but its Aetna insurance and Caremark PBM businesses support a…
Restaurant operators reported improving traffic, accelerating unit growth and higher advertising spend, while wage inflation ran 4-5% and…
Grupo Herdez, a MXN 15.2 billion Mexican food company, pairs dominant grocery brands with McCormick, Barilla and Hormel joint ventures.
Driven Brands’ 5,000-location auto-service network pairs strong Maintenance results with Car Wash and collision-unit fixes after DRVN fell…
Darden Restaurants posted 2.8% same-store sales growth as Olive Garden and LongHorn outperformed a softer casual-dining market, while…
Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.
Four Corners’ insider-backed asset sale cut shareholder proceeds to roughly 80% of its prior share price. A 2016 Wilh.
Alnylam’s 2022 50% phase-three gain faces FDA advisory-panel scrutiny over its amyloidosis drug’s label extension.
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.